Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats

One of the more serious complications following transplantation is the development of post-transplantation diabetes mellitus (PTDM), which has a major impact on the quality of life, with effects ranging from the control of glycemia times to increased susceptibility to infections and cardiovascular c...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian oral research 2007-12, Vol.21 (4), p.293-297
Main Authors: Nassar, Carlos Augusto, Nassar, Patricia Oehlmeyer, Andia, Denise Carleto, Guimarães, Morgana Rodrigues, Pepato, Maria Teresa, Spolidorio, Luis Carlos
Format: Article
Language:eng ; por
Subjects:
Animals
Blood Glucose - metabolism
Body Weight
DENTISTRY, ORAL SURGERY & MEDICINE
Diabetes Mellitus, Experimental - etiology
Disease Models, Animal
Glycemic Index
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Kidney Transplantation - immunology
Male
Random Allocation
Rats
Rats, Sprague-Dawley
Tacrolimus - administration & dosage
Tacrolimus - adverse effects
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the more serious complications following transplantation is the development of post-transplantation diabetes mellitus (PTDM), which has a major impact on the quality of life, with effects ranging from the control of glycemia times to increased susceptibility to infections and cardiovascular complications. It has been suggested that immunosuppressive therapy, mainly tacrolimus therapy, may be an important factor in the development of PTDM. There is a lack of studies that explore the effects of long-term tacrolimus on PTDM in animal protocols. The objective of this study was therefore to evaluate the effects of long-term therapy with tacrolimus in rats. One group was treated with tacrolimus, injected subcutaneously, in a daily dose of 1 mg/kg of body weight. The chosen dose was sufficient to achieve therapeutic tacrolimus serum levels. The experimental periods were 60, 120, 180 and 240 days. One group was used as control and received daily subcutaneous injections of saline solution during all periods. A tendency towards increased glycemia levels during the initial periods (60 and 120 days) was observed. However, at 180 and 240 days, the glycemia levels were not statistically different from that of the control group of the same period. It may thus be concluded that the deleterious effects of tacrolimus therapy on glycemia may be a time-related side effect.
ISSN:1806-8324
1807-3107
1807-3107
1806-8324
DOI:10.1590/s1806-83242007000400002